News Article
June 24, 2024 — The International Myeloma Foundation is proud to announce that its strong financial health and ongoing accountability and transparency has earned a Four-Star Rating from Charity Navigator. This rating designates the International Myeloma…
Videos
Abstract Title:
Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) versus VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)
Summary:
The Phase 3 IMROZ study compared the efficacy…
News Article
"I Have Insurance, Why Can't I Afford My Oral Anticancer Medications?" International Myeloma Foundation Highlights the Urgent Need for Cancer Drug Parity Act at Congressional Briefing
The Successful Briefing Addressed Insurance Coverage for Oral Anticancer Medications
Washington…
Videos
Abstract Title:
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Summary:
The DREAMM-…
Videos
Abstract Title:
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus Isa-Rd in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
Summary:
This abstract summarizes…
Videos
Abstract Title:
Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial
Summary:
The PERSEUS…
News Article
Global Collaboration Thrives at the IMF's 2024 Global Myeloma Action Network's Annual Summit
At its Global Myeloma Action Network (GMAN) annual summit from June 7-9, 2024, in Madrid, Spain, the International Myeloma Foundation (IMF) brought together 100 of the greatest minds in myeloma. The…
Videos
IMF's 15th Annual Gala Raised Nearly $700K to Support Myeloma Research
Together, we raised nearly $700,000 to benefit the Peter Boyle Research Fund, the IMF’s Black Swan Research Initiative®, and our educational programs. This significant contribution will accelerate groundbreaking myeloma…
Videos
Abstract title:
Cevostamab in Patients with RRMM Who Are Triple-Class Refractory and Have Received a Prior BCMA-Targeted ADC or CAR T-Cell: Initial Results from the Phase I/II CAMMA 2 Study
Summary:
Cevostamab, a FcRH5xCD3 bispecific antibody, has shown…
Videos
Myeloma Treatment with Bispecific Antibody Targets
Myeloma Made Simple: Bispecific Antibody Targets Made Simple
In this episode of Myeloma Made Simple, we explore how immunotherapy fights myeloma using the body's own defenses. Bispecific antibodies, the focus of this video, are drugs that…
News Article
International Myeloma Foundation (IMF) to Honor 2024 Kyle and Durie Achievement Awardees, Dr. Shaji Kumar and Dr. Francesca Gay
Awarding ceremonies to be held on June 11 at the 15th Annual IMWG Summit in Madrid, Spain
MADRID, SPAIN, June 11, 2024—The…
Page
In this series, IMF Chief Medical Officer Dr. Joseph Mikhael breaks down the complexities of myeloma into simple, easy-to-follow explanations. Whether it's about diagnosis, treatment options, or the latest research, Dr. Mikhael's approachable to difficult concepts helps patients, care partners, and…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the May 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Audio
An Interview with Myeloma Patient and Care Partner Adrienne and Chad Moore
Their insights on dealing with a multiple myeloma diagnosis as a patient and care partner team
In this episode of "A Day in the Life," Adrienne and Chad Moore, a patient and care partner…
Myeloma Made Simple: Bispecific Antibodies Made Simple | Bispecific Antibodies for Myeloma Treatment
Videos
Bispecific Antibodies for Myeloma Treatment
Myeloma Made Simple: Bispecific Antibodies Made Simple
Bispecific Antibodies Made Simple! Learn about bispecific antibodies, a cutting-edge class of drugs in myeloma treatment, designed to harness the patient's immune system to combat the disease…
News Article
According to a press release from Sanofi, "The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd…
Videos
Managing Myeloma Side Effects with Xpovio (Selinexor)
Myeloma Made Simple: Selinexor Side Effect Management Made Simple
Selinexor Side Effect Management Made Simple! In this video, IMF Chief Medical Officer Dr. Joseph Mikhael discusses the latest insights on Xpovio® (Selinexor…
News Article
International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma
Twelve Student-Mentor Pairs to Participate in 2024 NMA Annual Convention and Scientific Assembly in August
The International Myeloma Foundation (IMF) is proud to…
Videos
Selinexor for Multiple Myeloma Treatment
Myeloma Made Simple: Xpovio (Selinexor) Made Simple
Xpovio (Selinexor) Made Simple! Join Dr. Joseph Mikhael to learn about Xpovio® (Selinexor), a drug in the treatment of myeloma that belongs to a new class of drugs called XPO1 inhibitors.…
Videos
The Role of ASCT in the Frontline Setting for African-American Patients
In this week's episode of Ask Dr. Durie, myeloma expert Dr. Brian G.M. Durie discusses the role of ASCT in the frontline setting for African-American patients.
Immune therapies like CAR T-cell therapy are being…
News Article
On Thursday, April 25, Nurse Leadership Board (NLB) members Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, BMTCN®, FAAN, FAPO; Kevin Brigle, PhD, NP; Patricia Mangan, RN, MSN, APRN-BC; and Donna Catamero, ANP-BC, OCN presented Case Studies for Nurses: New and Therapies and Regimens for Patients With…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the April 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Does MGUS Require Bone Marrow Testing?
A new study from Iceland, part of the IMF's iStopMM project, distinguishes between patients who require bone marrow testing and those who can be safely monitored without immediate bone marrow testing.
The study accurately predicted that…
News Article
Patient Advocates Meet with Legislators
YOU can help ensure that research of myeloma and other cancers receives adequate funding
By Emma Hatcher, IMF Global Vice President, Patient Engagement & Advocacy
Have you ever thought about how you can help…
News Article
With Over $675,000 Raised, the Gala Benefits the Peter Boyle Research Fund and Celebrates Groundbreaking Myeloma Research, Education, Support, and Advocacy
STUDIO CITY, Calif. April 25, 2024—On Thursday, April 18, The International Myeloma Foundation (IMF) held…
News Article
According to an April 22 press release from Johnson & Johnson, the European Commission (EC) has approved CARVYKTI (ciltacabtagene autoleucel; cilta cel) as the “first BCMA-targeted treatment for relapsed and refractory multiple myeloma (RRMM) patients who have received at least one…
Videos
Patient Relapse During Clinical Trial
In today's Ask Dr. Durie video, myeloma expert Dr. Brian G.M. Durie discusses what should be done if a patient relapses while in a clinical trial.
Biochemical relapse means that the level of myeloma protein has increased by at least 25% and…
Videos
CRAB and pre-CRAB Criteria in Myeloma Diagnosis
In this week's Ask Dr. Durie episode, myeloma expert Dr. Brian G.M. Durie defines CRAB and pre-CRAB criteria in myeloma diagnosis and how they affect treatment decision-making.
CRAB criteria are vital for diagnosing myeloma: 'C'…
News Article
International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community.
This conclusion is the result of almost 10 years of…
Page
People of Color Face Disparities in Access to Clinical Trials, New Drugs, and New Therapies Data from the 2015-2019 FDA Drug Trials Snapshot showed that White people comprise over 70 percent of clinical trial participants even though almost 40 percent of the U.S. population is comprised of…
Videos
The Value of MRD Testing for Myeloma
In today's Ask Dr. Durie video, myeloma expert Dr. Brian G.M. Durie discusses the value of minimal residual disease testing for myeloma patients.
MRD testing detects residual myeloma after treatment, offering valuable insights into disease status…
News Article
STUDIO CITY, April 11, 2024—The International Myeloma Foundation (IMF) and Black Swan Research Initiative® (BSRI) announced the recently published cohort study by the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) team on the “Development of a Multivariable Model…
News Article
In an April 5 press release from Johnson & Johnson, it was announced that the FDA "approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a…
News Article
According to this press release from Bristol Myers Squibb and 2seventy bio, "On April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior…
Videos
Gain valuable insights about nutrition in this Q&A replay from myeloma specialist Dr. Urvi A. Shah, who is spearheading research aimed at developing dietary guidelines for hematological malignancies such as multiple myeloma. Hear Dr. Shah's expert opinion on plant-based foods and supplements…
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth!
News Article
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth!
2024 Myeloma Action Month Global Campaign Brings Wave of Myeloma Awareness to 36 Countries Worldwide
STUDIO CITY, CA, April 4, 2024 — At the conclusion of this year’…
Videos
ODAC Hearing on Early Use of CAR T-cell Therapy
Myeloma expert Dr. Brian G.M. Durie discusses the Oncologic Drugs Advisory Committee (ODAC) hearing's impact on the use of early CAR T-cell treatment in myeloma.
Concerns emerged regarding the complexities of bridging therapy,…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the March 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
IMF Grassroots Patient Advocacy
YOU can help drive meaningful change for patients with myeloma
By Emma Hatcher, IMF Global Vice President, Patient Engagement & Advocacy
Every day, critical healthcare issues are discussed on Capitol Hill, in the White…
Videos
International Myeloma Foundation (IMF) Vice President of Support Groups Robin Tuohy will moderate presentations by Joanna Fawzy Doran, Esq., Triage Cancer CEO and Cancer Rights Attorney. …
Videos
Replay the enlightening Myeloma Action Month live event with IMF NLB Member Beth Faiman as she shares personal anecdotes and addresses viewers' pressing myeloma questions. Beth's expertise shines through as she delves into discussions about treatment options, symptom management, and the latest…
Videos
Replay the Myeloma Action Month Q&A session live from the IMF's Patient and Family Seminar with Dr. Joseph Mikhael and Dr. Gurbakhash Kaur. In this engaging recording, Dr. Mikhael and Dr. Kaur shared valuable insights into the latest developments in multiple myeloma treatment and research. From…
News Article
In this March 20, 2024 press release from Bristol Myers Squibb, it was announced that "the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two…
Videos
Considerations for Multiple Myeloma Immune Therapy
Myeloma expert Dr. Brian G.M. Durie discusses how immune therapy targets, side effects, and monitoring should be considered in multiple myeloma treatment.
Dr. Durie discusses considerations for immune therapy for the treatment of…
News Article
Myeloma Survivor, Advocate, and… Disruptor!
Kent Oliver supports the transformative potential of the IMF’s innovative Myeloma Knowledge Platform
By Sylvia Dsouza, IMF Vice President, Development
Oliver, a longstanding donor, resilient myeloma survivor,…
News Article
According to this March 15, 2024, press release from Bristol Myers Squibb and 2seventy bio, "the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients…
News Article
In a March 15, 2024 press release from Johnson & Johnson, it was reported that "the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommends CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory…
Videos
IMF Patient and Family Seminars gather highly esteemed global myeloma researchers and healthcare professionals under one roof to share the latest developments in the field of myeloma and to answer your questions about the disease firsthand.